Marinus Pharmaceuticals

Marinus Pharmaceuticals reported Phase III RAISE trial results for IV ganaxolone in treating refractory status epilepticus (RSE), showing significant seizure cessation effects but not preventing IV anesthesia progression. The trial demonstrated a median reduction in EEG seizure burden and comparable serious adverse events, with more hypotension in the ganaxolone group.

Philadelphia-area life sciences industry nears 900 layoffs since 2022 due to reduced investment and focus on late-stage development, with companies like Verrica Pharmaceuticals and Spark Therapeutics cutting jobs.

Marinus Pharmaceuticals presented Phase 3 RAISE trial data on IV ganaxolone for refractory status epilepticus (RSE) at the Neurocritical Care Society Annual Meeting, showing rapid cessation of SE in 80% of patients within 30 minutes, though failing to meet the second co-primary endpoint.

Cognitive Research Corporation (CRC) adds Dr. Albena Patroneva, Dr. Mark Versavel, Dr. Sandeep Vaishnavi, and Dr. Djouher Hough to its medical leadership team, enhancing expertise in neurology, psychiatry, analgesia, and psychedelic research.

Opthea Limited has made executive leadership changes in finance and commercial areas, and hired senior staff in biometrics, clinical operations, and market access. These changes are in preparation for the anticipated clinical trial data in 2025. Key hires include Dan Geffken as interim CFO, Mike Campbell as CCO, Dayong Li as SVP of Biometrics, Jen Watts as VP of Global Clinical Operations, and Anthony Bonifazio as VP of Market Access.

Marinus Pharmaceuticals to present ZTALMY® (ganaxolone) progress for tuberous sclerosis complex (TSC) at Investor and Analyst Day, including TrustTSC Phase 3 trial data expected Q4 2024, NDA filing targeted for April 2025, low discontinuation rate (6.2%), and 56% median seizure frequency reduction in Phase 2 TSC trial extension.